文献速递眼底病与葡萄膜炎

从PACORES看增殖性糖尿病视网膜病变管理:拉丁美洲与西班牙数据——2020年Asbury讲座

LESSONS LEARNED FROM PACORES IN PROLIFERATIVE DIABETIC RETINOPATHY MANAGEMENT, DATA FROM LATIN AMERICA AND SPAIN: The Asbury Lecture 2020.
PubMed 文献 · Retina · 2022-01-01

本文综述增殖性糖尿病视网膜病变(PDR)治疗选择,聚焦泛美视网膜协作研究组(PACORES)的真实世界数据。临床试验显示玻璃体腔抗VEGF治疗对PDR不劣于全视网膜光凝(PRP),但停药后PDR快速复发。真实世界前瞻性研究中,既往PRP后接受抗VEGF治疗的患者较单用抗VEGF治疗有更高的PDR持续消退率。鉴于抗VEGF疗效短暂,随访无法保证时PDR可能复发进展,应考虑较温和的即时PRP联合抗VEGF方案。

要点

  • 抗VEGF治疗PDR不劣于PRP,但停药后PDR快速复发。
  • 真实世界研究显示既往PRP后抗VEGF者PDR持续消退率更高。
  • 随访无法保证时,可考虑即时PRP联合抗VEGF的联合方案。

核心结论

  • 抗VEGF治疗PDR疗效短暂,随访无法保证时存在视网膜新生血管复发和PDR进展风险。
  • 应考虑较温和的即时全视网膜光凝联合抗VEGF治疗的联合方案。

研究设计与样本

  • 文献综述,聚焦泛美视网膜协作研究组(PACORES)的真实世界数据。

主要发现

  • 临床试验和既往文献报告玻璃体腔抗VEGF治疗PDR不劣于全视网膜光凝这一金标准。
  • 停用抗VEGF治疗后PDR快速复发,在易失访的糖尿病人群中尤为重要。
  • 真实世界前瞻性研究中,既往全视网膜光凝后接受抗VEGF治疗的患者较单用抗VEGF治疗有更高的PDR持续消退率。

临床怎么用

  • 对随访无法保证的糖尿病患者,抗VEGF单药治疗需警惕PDR复发和进展风险。
  • 可考虑较温和的即时全视网膜光凝联合抗VEGF治疗的联合方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the current literature on the management of proliferative diabetic retinopathy (PDR) and the challenges in the real-world setting. METHODS: A review of the literature was performed on the therapeutic options for PDR, with a focus on the real-world data presented by the Pan-American Collaborative Retina Study Group. RESULTS: Data from clinical trials and previous literature have reported that intravitreal antivascular endothelial growth factor (anti-VEGF) therapy is noninferior to the gold standard panretinal photocoagulation for treating PDR. However, PDR recurs rapidly after cessation of anti-VEGF therapy. This is especially important in the context of the diabetic population that is prone to loss to follow-up. In a real-world, prospective study, patients with prior panretinal photocoagulation followed by anti-VEGF therapy had higher rates of sustained PDR regression relative to anti-VEGF therapy alone. CONCLUSION: Owing to its transient therapeutic effect, anti-VEGF therapy in patients with diabetes can present a risk of recurrent retinal neovascularization and progression of PDR if follow-up cannot be guaranteed. A combined paradigm with less aggressive, immediate panretinal photocoagulation followed by anti-VEGF therapy should be considered in this population.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Arevalo JF, Beatson B. LESSONS LEARNED FROM PACORES IN PROLIFERATIVE DIABETIC RETINOPATHY MANAGEMENT, DATA FROM LATIN AMERICA AND SPAIN: The Asbury Lecture 2020. Retina. 2022. PMID: 34081638. doi:10.1097/IAE.0000000000003226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。